TOS Past Presidents Comment on SELECT Study Results
ROCKVILLE, Md., Nov. 14, 2023 /PRNewswire/ -- New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society (TOS) and published in The New England Journal of Medicine.
- Apovian is professor at Harvard Medical School and co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, Boston, Mass.
- I felt that the audience had confidence in the results because of the precision with which the study was executed.
- To view a copy of the study titled "Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes," visit The New England Journal of Medicine website.
- Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity.